Citius OncologyCTOR -6.07%10 PS Ratio is 10.19 as of Jun. 28, 2026, which is 32% below its 10-year median of 14.94. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 949 Drug Manufacturers companies, Citius Oncology ranks worse than 87.99% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Citius Oncology's share price is $0.6319.
Citius Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.06. Hence, Citius Oncology's PS Ratio for today is 10.19.
Good Sign:
Citius Oncology Inc stock PS Ratio (=10.19) is close to 1-year low of 10.19.
The historical rank and industry rank for Citius Oncology's PS Ratio or its related term are showing as below:
CTOR'
s PS Ratio Range Over the Past 10 Years
Min: 10.19 Med: 14.94 Max: 27.11
Current: 10.19
During the past 4 years, Citius Oncology's highest PS Ratio was 27.11. The lowest was 10.19. And the median was 14.94.
CTOR's PS Ratio is ranked worse than 87.99% of 949
companies
in the Drug Manufacturers industry
Industry Median: 2.2
vs CTOR: 10.19
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Citius Oncology PS Ratio Related Terms
Citius Oncology PS Ratio Historical Data
* Premium members only.
The historical data trend for Citius Oncology's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Oncology PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's PS Ratio distribution charts can be found below:
* The bar in red indicates where Citius Oncology's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Citius Oncology's Share Price of today is $0.6319. Citius Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Citius Oncology (CTOR) has a PS Ratio of 10.19 as of Jun. 28, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Citius Oncology and its competitors. This is 32% below median its historical median of 14.94. Over the past decade, Citius Oncology's PS Ratio has ranged from 10.19 to 27.11. According to the industry distribution chart, Citius Oncology ranks #835 out of 949 companies in the Drug Manufacturers industry, placing it in the top 88%.
Is Citius Oncology's PS Ratio too high?
Citius Oncology's current PS Ratio of 10.19 is 32% below median its 10-year median of 14.94. Over the past 10 years, this metric has ranged from a low of 10.19 to a high of 27.11. The Drug Manufacturers industry median PS Ratio is 2.20. Citius Oncology's value of 10.19 is 363.2% above this industry median. Based on the distribution chart, Citius Oncology ranks #835 out of 949 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's PS Ratio compare to INCR and BGM?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #835 out of 949 companies for PS Ratio. This places Citius Oncology in the lower half of its industry. The industry median PS Ratio is 2.20. Citius Oncology's value of 10.19 is 363.2% above this benchmark. Historically, Citius Oncology's own PS Ratio has ranged from 10.19 to 27.11 over the past decade. While the company's 10-year median is 14.94 vs. the industry median of 2.20, Citius Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.20, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Citius Oncology's current PS Ratio of 10.19 is 363.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Citius Oncology and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Oncology's current PS Ratio is 10.19, which is 32% below median its own 10-year median of 14.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current PS Ratio of 10.19. The current PS Ratio is 10.19, which is 32% below median its 10-year median of 14.94 and 363.2% above the Drug Manufacturers industry median of 2.20. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Citius Oncology (CTOR), the current PS Ratio is 10.19 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score
Get the complete analysis for CTOR
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTOR has been successfully added to your 
